Keywords
Type A/therapeutic use
MigraineDisorders/prevention& control
MigraineDisorders/drugtherapy
ChronicDisease
SystematicReviews as Topic
How to Cite
Abstract
Introduction: Migraine is a complex neurological disorder that causes recurrent, localized headaches and is associated with hyperstimulation of the muscles in the frontal, temporal, occipital, and trapezius regions. Botulinum toxin acts on the motor plate by blocking the action of acetylcholine, thereby producing an analgesic effect in these patients. Materials and methods: A systematic review will be conducted using the PubMed and Scielo electronic databases. The search criteria were studies and reviews published between 2014 and April 2020 to identify transitional research focused on the use of botulinum toxin in patients with chronic migraine. Results: Nine articles that met the criteria for evaluating the efficacy of chronic migraine treatment using Onabotulimumtoxin A were included. An average of three cycles of the PREEMPT treatment protocol were performed. The mean age was 47 years, and 82.5% were women. The frequency of headache days/month and its intensity were significantly reduced by 30 to 50%, and this improvement was maintained over time. Conclusion: Randomized studies have shown that long-term, fixed-dose, fixed-site intramuscular injection therapy with botulinum toxin A is a safe and effective procedure with insignificant complications in appropriately selected patients.
References
1. Herd CP, Tomlinson CL, Rick C, Scotton WJ, Edwards J, Ives N, et al. Botulinum toxins for the prevention of migraine in adults. Cochrane Database Syst Rev. 2018;6:CD011616.
2. Olesen J. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.
3. Whitcup SM, Turkel CC, Degryse RE, Brin MF. Development of onabotulinumtoxinA for chronic migraine. Ann N Y Acad Sci. 2014;1329(1):67–80.
4. Silberstein SD. The use of botulinum toxin in the management of headache disorders. Semin Neurol. 2016;36(1):92–98.
5. Frampton JE, Silberstein S. OnabotulinumtoxinA: a review in the prevention of chronic migraine. Drugs. 2018;78(5):589–600.
6. Menezes C, Rodrigues B, Magalhães E, Melo A. Botulinum toxin type A in refractory chronic migraine: an open-label trial. Arq Neuropsiquiatr. 2007;65(3A):596–600.
7. Green MW, Rothrock JF. An academic debate: onabotulinumtoxinA for chronic migraine: PREEMPT-derived vs “customized” dosing/injection paradigm. Toxicon. 2018;147:1–6.
8. Gago-Veiga AB, Santos-Lasaosa S, Cuadrado ML, Guerrero L, Irimia P, Láinez JM, et al. Evidence and experience with onabotulinumtoxinA in chronic migraine: recommendations for daily clinical practice. Neurologia. 2019;34(6):408–417.
9. Ornello R, et al. Real-life data on onabotulinumtoxinA in chronic migraine. J Headache Pain. 2020;21:40.
10. Finkel AG. Botulinum toxin and the treatment of headache: a clinical review. Toxicon. 2015;107:114–119.
11. Szok D, Csáti A, Vécsei L, Tajti J. Treatment of chronic migraine with onabotulinumtoxinA: mode of action, efficacy and safety. Toxins (Basel). 2015;7(7):2659–2673.
12. Ornello R, Guerzoni S, Baraldi C, Evangelista L, Frattale I, Marini C, et al. Sustained response to onabotulinumtoxinA in patients with chronic migraine: real-life data. J Headache Pain. 2020;21(1):1–10.
13. Hay E, Dhe L, Se O. Tratamiento farmacológico de la migraña. Rev Neurol. 2014;59:54–58.
14. Khalil M, Zafar HW, Quarshie V, Ahmed F. Prospective analysis of the use of onabotulinumtoxinA (BOTOX) in the treatment of chronic migraine: real-life data in 254 patients from Hull, UK. J Headache Pain. 2014;15(1):54.
15. Kollewe K, Escher C, Wulff D, Fathi D, Paracka L, Mohammadi B, et al. Long-term treatment of chronic migraine with onabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting. J Neural Transm. 2016;123:533–540.
16. Armanious M, Khalil N, Lu Y, Jimenez-Sanders R. Erenumab and OnabotulinumtoxinA Combination Therapy for the Prevention of Intractable Chronic Migraine without Aura: A Retrospective Analysis. Journal of Pain and Palliative Care Pharmacotherapy 2021;35:1–6. https://doi.org/10.1080/15360288.2020.1829249.
17. Belvís R, Irimia P, Pozo-Rosich P, González-Oria C, Cano A, Viguera J, et al. MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention. Journal of Headache and Pain 2021;22. https://doi.org/10.1186/s10194-021-01267-x.
18. Blumenfeld AM, Frishberg BM, Schim JD, Iannone A, Schneider G, Yedigarova L, et al. Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review. Pain and Therapy 2021;10:809–26. https://doi.org/10.1007/s40122-021-00264-x.
19. Chiang C-C, Arca KN, Dunn RB, Girardo ME, Quillen JK, Dodick DW, et al. Real-world efficacy, tolerability, and safety of ubrogepant. Headache 2021;61:620–7. https://doi.org/10.1111/head.14062.
20. Cohen F, Armand C, Lipton RB, Vollbracht S. Efficacy and Tolerability of Calcitonin Gene-Related Peptide-Targeted Monoclonal Antibody Medications as Add-on Therapy to OnabotulinumtoxinA in Patients with Chronic Migraine. Pain Medicine (United States) 2021;22:1857–63. https://doi.org/10.1093/pm/pnab093.
21. Floresta G, Patamia V, Gentile D, Molteni F, Santamato A, Rescifina A, et al. Repurposing of FDA-Approved Drugs for Treating Iatrogenic Botulism: A Paired 3D-QSAR/Docking Approach†. ChemMedChem 2020;15:256–62. https://doi.org/10.1002/cmdc.201900594.
22. Kawata AK, Shah N, Poon J-L, Shaffer S, Sapra S, Wilcox TK, et al. Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study. Headache 2021;61:438–54. https://doi.org/10.1111/head.14053.
23. Khanal S, Underwood M, Naghdi S, Brown A, Duncan C, Matharu M, et al. A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine. Journal of Headache and Pain 2022;23. https://doi.org/10.1186/s10194-022-01492-y.
24. Lambru G, Hill B, Murphy M, Tylova I, Andreou AP. A prospective real-world analysis of erenumab in refractory chronic migraine. Journal of Headache and Pain 2020;21. https://doi.org/10.1186/s10194-020-01127-0.
25. Mechtler L, Saikali N, McVige J, Hughes O, Traut A, Manack Adams AM. Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine. Frontiers in Neurology 2022;12. https://doi.org/10.3389/fneur.2021.788159.
26. Ornello R, Guerzoni S, Baraldi C, Evangelista L, Frattale I, Marini C, et al. Sustained response to onabotulinumtoxin A in patients with chronic migraine: Real-life data. Journal of Headache and Pain 2020;21. https://doi.org/10.1186/s10194-020-01113-6.
27. Pensato U, Baraldi C, Favoni V, Cainazzo MM, Torelli P, Querzani P, et al. Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache. Neurological Sciences 2022;43:1273–80. https://doi.org/10.1007/s10072-021-05426-5.
28. Raffaelli B, Kalantzis R, Mecklenburg J, Overeem LH, Neeb L, Gendolla A, et al. Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study. Frontiers in Neurology 2020;11. https://doi.org/10.3389/fneur.2020.00417.
29. Robblee J, Devick KL, Mendez N, Potter J, Slonaker J, Starling AJ. Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine. Headache 2020;60:2014–25. https://doi.org/10.1111/head.13951.
30. Shaterian N, Shaterian N, Ghanaatpisheh A, Abbasi F, Daniali S, Jahromi MJ, et al. Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review. Pain Research and Management 2022;2022. https://doi.org/10.1155/2022/3284446.
31. Talbot J, Stuckey R, Crawford L, Weatherby S, Mullin S. Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment – real world outcomes. Journal of Headache and Pain 2021;22. https://doi.org/10.1186/s10194-020-01214-2.
32. Torres-Ferrús M, Gallardo VJ, Alpuente A, Pozo-Rosich P. Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA. Journal of Headache and Pain 2020;21. https://doi.org/10.1186/s10194-020-01157-8.
33. Winner PK, Kabbouche M, Yonker M, Wangsadipura V, Lum A, Brin MF. A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine. Headache 2020;60:564–75. https://doi.org/10.1111/head.13754.
34. Wong H-T, Khalil M, Ahmed F. OnabotulinumtoxinA for chronic migraine during pregnancy: a real world experience on 45 patients. Journal of Headache and Pain 2020;21. https://doi.org/10.1186/s10194-020-01196-1.
35. Al-Hashel JY, Ibrahim Ismail II. Impact of coronavirus disease 2019 (COVID-19) pandemic on patients with migraine: a web-based survey study. Journal of Headache and Pain 2020;21. https://doi.org/10.1186/S10194-020-01183-6.
36. Castrillo Sanz A, Morollón Sánchez-Mateos N, Simonet Hernández C, Fernández Rodríguez B, Cerdán Santacruz D, Mendoza Rodríguez A, et al. Experiencia con toxina botulínica en la migraña crónica. Neurologia. 2016;31:1–7.
37. Domínguez C, Pozo-Rosich P, Leira Y, Leira R. Unilateral pain and shorter migraine duration as predictors of response to onabotulinumtoxinA in chronic migraine. Eur J Neurol. 2018;25(4):e48.
38. Schiano di Cola F, Caratozzolo S, Liberini P, Rao R, Padovani A. Response predictors in chronic migraine: medication overuse and depressive symptoms negatively impact onabotulinumtoxinA. Eur J Neurol. 2019;26:1–8.
39. Herd CP, Tomlinson CL, Rick C, Scotton WJ, Edwards J, Ives NJ, et al. Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine. BMJ Open. 2019;9(7):e027953.
40. Frampton JE, Silberstein S. OnabotulinumtoxinA: a review in the prevention of chronic migraine. Drugs. 2018;78(5):589–600.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Tiago Goulart Appel, João Francisco De Oliveira Neto (Author)